Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study
Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
Study Objectives are:
To assess the safety of osimertinib treatment continuation during irradiation therapy for
palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after
concomitant osimertinib and irradiation of tumor sites.
To assess the efficacy of osimertinib treatment continuation during irradiation therapy for
palliation or oligoprogressive disease.
To investigate Quality of Life during and after irradiation therapy and concomitant
osimertinib.